TENX
$15.53+1.55 (+11.09%)
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatme...
Recent News
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
Tenax Therapeutics: Q4 Earnings Snapshot
The Chapel Hill, North Carolina-based company said it had a loss of 38 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.26 per share.
Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference
Executives from Tenax Therapeutics (NASDAQ:TENX) outlined progress on the company’s Phase III development program for levosimendan in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) during a fireside chat at Guggenheim’s Emerging Outlook Biotech Confe
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick
Tenax Therapeutics Inc (NASDAQ:TENX) is one of the best performing micro cap stocks in 2025. On December 17, Guggenheim raised its price target on Tenax Therapeutics Inc (NASDAQ:TENX) to $25 from $14 and maintained a Buy rating. The firm stated that its decision to nearly double the price target for Tenax relies on a specific […]
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...